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Following publication of the original article \[[@CR1]\], the authors noticed an error in the values for 'Hypersensitivity SMQ' and 'Rash' in Table [7](#Tab1){ref-type="table"}. The data presented for 'Hypersensitivity SMQ' and 'Rash' were inadvertently the events that were potentially hypersensitivity rather than the events that were likely hypersensitivity after medical review. The table legend and discussion of the data in the text were and are correct. Table 7Percentage of patients in integrated double-blind studies who experienced a hypersensitivity event^a,b^GalcanezumabPlacebo\
*N* = 1451\
n (%)120 mg\
*N* = 705\
n (%)240 mg\
*N* = 730\
n (%)Hypersensitivity SMQ40 (2.8)34 (4.8)^c^32 (4.4)^c^ Rash15 (1.0)5 (0.7)7 (1.0) Injection site rash2 (0.1)6 (0.9)^c^4 (0.6) Dermatitis contact4 (0.3)3 (0.4)4 (0.6) Rhinitis allergic3 (0.2)3 (0.4)4 (0.6) Hypersensitivity0 (0.0)3 (0.4)^c^2 (0.3)^c^ Injection site hypersensitivity0 (0.0)1 (0.1)3 (0.4)^c^ Dermatitis allergic0 (0.0)3 (0.4)^c^0 (0.0) Eczema3 (0.2)1 (0.1)2 (0.3) Rash pruritic0 (0.0)2 (0.3)^c^1 (0.1) Urticaria5 (0.3)2 (0.3)1 (0.1) Injection site urticaria1 (0.1)1 (0.1)1 (0.1) Rash generalized1 (0.1)1 (0.1)1 (0.1) Rash papulosquamous0 (0.0)1 (0.1)1(0.1) Dermatitis atopic1 (0.1)0 (0.0)1(0.1) Eye allergy0 (0.0)1 (0.1)0 (0.0) Pruritus allergic0 (0.0)1 (0.1)0 (0.0) Rash erythematous1 (0.1)0 (0.0)1 (0.1) Rash maculo-papular1 (0.1)1 (0.1)0 (0.0) Bronchospasm1 (0.1)0 (0.0)0 (0.0) Conjunctivitis allergic1 (0.1)0 (0.0)0 (0.0) Drug hypersensitivity1 (0.1)0 (0.0)0 (0.0)Abbreviations: *MedDRA* Medical Dictionary for Regulatory Activities, *N* number of patients in the analysis population, *n* number of patients within each specific category, *SMQ* standardized MedDRA query^a^These are likely events per medical review^b^Categorized by narrow standardized MedDRA®^b^ (v.19.1) query search terms. MedDRA®, the certified Medical Dictionary for Regulatory Activities terminology, is the international medical terminology developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use^c^Indicates a statistically significant difference (*P* \< 0.05) compared with placebo
